MichelleAElliottMD
Hematology • Rochester, MNHematologic Oncology
Associate Professor, Internal Medicine, Mayo Medical School
Dr. Elliott is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1995
University of Dublin Trinity CollegeClass of 1991, MB BCh
Certifications & Licensure
MN State Medical License 1994 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 5 citationsCSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes.Evandro D. Bezerra, Terra L. Lasho, Christy Finke, Antoine N. Saliba, Michelle A. Elliott
Blood Cancer Journal. 2021-03-11 - 11 citationsOne thousand patients with essential thrombocythemia: the Mayo Clinic experience.Naseema Gangat, Omer Karrar, Aref Al-Kali, Kebede H Begna, Michelle A Elliott
Blood Cancer Journal. 2024-01-18 - 241 citationsPrognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral bl...Angela Dispenzieri, Morie A. Gertz, Robert A. Kyle, Martha Q. Lacy, Mary F. Burritt
Blood. 2004-09-15
Abstracts/Posters
- Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be BeneficialMichelle A Elliott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition SyndromesMichelle A Elliott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International CollaborationMichelle A Elliott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Authored Content
- Prognostic Impact of ASXL1 Mutations in Patients with Myelodysplastic Syndromes and Multilineage Dysplasia with or Without Ring SideroblastsJuly 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
